


CLAIMS

1. A compound of formula(I)



wherein

R represents halogen, C₁₋₄ alkyl, cyano, C₁₋₄ alkoxy, trifluoromethyl or trifluoromethoxy;

10 R₁ represents a 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms, or R₁ represents a 4, 5 or 6 membered heterocyclic group, wherein saids 5 or 6 membered heteroaryl or the 4, 5 or 6 membered heterocyclic group may optionally be substituted by one to three substituents, which may be the same or different, selected from (CH₂)_pR₆, wherein p is zero or an integer from 1 to 4 and R₆ is selected from:

halogen,

C₁₋₄alkoxy,

C₁₋₄alkyl,

C₃₋₇cycloalkyl,

20 C₁₋₄ alkyl optionally substituted by halogen, cyano or C₁₋₄ alkoxy,

hydroxy,

cyano,

nitro,

trifluoromethyl,

25 carboxy,

NH(C₁₋₄ alkyl),

N(C₁₋₄ alkyl)₂

NH(C₃₋₇ cycloalkyl),

N(C₁₋₄ alkyl)(C₃₋₇ cycloalkyl);

30 NH(C₁₋₄alky)OC₁₋₄alkoxy,

OC(O)NR₇R₈,

NR₈C(O) R₇ or

C(O)NR₇R₈;

R₂ represents hydrogen, or C₁₋₄ alkyl;

35 R₃ and R₄ independently represent hydrogen, C₁₋₄ alkyl or R₃ together with R₄ represents C₃₋₇ cycloalkyl;

R_5 represents trifluoromethyl, $S(O)qC_1\text{--}4$ alkyl, $C_1\text{--}4$ alkyl, $C_1\text{--}4$ alkoxy, trifluoromethoxy, halogen or cyano;

R_7 and R_8 independently represent hydrogen, $C_1\text{--}4$ alkyl or $C_3\text{--}7$ cycloalkyl;

L is a single or a double bond;

5 n is an integer from 1 to 3;

m is zero or an integer from 1 to 3;

q is zero or an integer from 1 to 2;

provided that

a) when L is a double bond, R_1 is not an optionally substituted 5 or 6 membered 10 heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms;

b) the group R_1 is linked to the carbon atom shown as * via a carbon atom;

and

15 c) when the heteroatom contained in the group R_1 is substituted, p is not zero;

and pharmaceutically acceptable salts and solvates thereof.

2. A compound as claimed in claim 1 wherein R is halogen (e.g. fluorine or chlorine) and/or a $C_1\text{--}4$ alkyl (e.g. methyl) group and n is an integer from 1 to 2.

20

3. A compound as claimed in claim 1 or claim 2 wherein R_5 is trifluoromethyl, methyl, methoxy, bromine, chlorine or fluorine atom and m is an integer from 1 to 2.

25

4. A compound as claimed in any of claims 1 to 3 wherein R_1 is piperidyl, morpholinyl, 1,2,3,6-tetrahydro-4-pyridinyl, pyridyl or pyrrolidinyl.

30

5. A compound as claimed in any of claims 1 to 4 wherein R is halogen (e.g. fluorine or chlorine) and/or a $C_1\text{--}4$ alkyl (e.g. methyl) group and n is an integer from 1 to 2; R_1 is piperidyl, 2-morpholinyl, 1,2,3,6-tetrahydro-4-pyridinyl, pyridyl or pyrrolidinyl and wherein R_1 is optionally substituted by one or two groups selected from halogen (e.g. fluorine), $C_1\text{--}4$ alkyl (e.g. methyl) or ethyl, $C_1\text{--}4$ alkoxy; R_2 and R_3 are independently hydrogen or methyl; R_4 is hydrogen, methyl or together with R_3 is cyclopropyl and R_5 is trifluoromethyl, methyl, methoxy, bromine, chlorine or fluorine atom and m is preferably an integer from 1 to 2.

35

6. A compound selected from:

N -(3,5-Bis-trifluoromethyl-benzyl)-3-(4-fluoro-phenyl)- N -methyl-3-piperidin-4-yl-propionamide;

N -(3,5-Dichloro-benzyl)-3-(4-fluoro-phenyl)- N -methyl-3-piperidin-4-yl-propionamide;

40

N -[1-(3,5-Dichloro-phenyl)-ethyl]-3-(4-fluoro-phenyl)- N -methyl-3-piperidin-4-yl-propionamide;

N-[1-(3,5-Dichloro-phenyl)-ethyl]-3-(4-fluoro-phenyl)-N-methyl-3-[1-(2-methoxyethyl)-piperidin-4-yl]-propionamide;

N-(3,5-Dichloro-benzyl)-3-(4-fluoro-phenyl)-3-(4-fluoro-piperidin-4-yl)-N-methyl-propriionamide;

5 N-[{3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-N-methyl-3-{1-[2-(methyloxy)ethyl]-4-piperidinyl}propionamideN-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-N-methyl-3-(4-piperidinyl)propanamide;

N-{1-[3,5-bis(trifluoromethyl)phenyl]-1-methylethyl}-3-(4-fluorophenyl)-3-(4-piperidinyl)propionamide;

10 N-[{3-bromo-4-(methyloxy)phenyl]methyl}-3-(4-fluorophenyl)-N-methyl-3-(4-piperidinyl)propionamide;

N-[{3,5-dimethylphenyl]methyl}-3-(4-fluorophenyl)-N-methyl-3-(4-piperidinyl)propionamide;

N-[{3,4-dibromophenyl]methyl}-3-(4-fluorophenyl)-N-methyl-3-(4-piperidinyl)propionamide;

N-[{3-fluoro-2-methylphenyl]methyl}-3-(4-fluorophenyl)-N-methyl-3-(4-piperidinyl)propionamide;

15 N-[{2-chloro-3-(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-N-methyl-3-(4-piperidinyl)propionamide;

N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-N-methylpropionamide;

20 N-[{3,5-dibromophenyl]methyl}-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-N-methylpropionamide;

N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(2,4-dichlorophenyl)-3-(4-fluoro-4-piperidinyl)-N-methylpropionamide;

N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluoro-2-methylphenyl)-3-(4-fluoro-4-piperidinyl)-N-methylpropionamide;

25 N-[{3,5-dibromophenyl]methyl}-3-(4-fluoro-2-methylphenyl)-3-(4-fluoro-4-piperidinyl)-N-methylpropionamide;

N-[{3,5-dibromophenyl]methyl}-3-(3,4-dichlorophenyl)-3-(4-fluoro-4-piperidinyl)-N-methylpropionamide;

N-[{3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-N-methylpropionamide;

30 N-[{3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-N-methylpropionamide;

3-(4-chlorophenyl)-N-[{3,5-dibromophenyl]methyl}-3-(4-fluoro-4-piperidinyl)-N-methylpropionamide;

N-[{3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-N-methyl-3-(3-piperidinylidene)propionamide;

35 N-[{3,5-dibromophenyl]methyl}-3-(4-fluorophenyl)-N-methyl-3-(4-piperidinylidene)propionamide;

N-[{3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluoro-2-methylphenyl)-N-methyl-3-(1,2,3,6-tetrahydro-4-pyridinyl)propionamide;

40 N-{(1*R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluoro-2-methylphenyl)-N-methyl-3-(1,2,3,6-tetrahydro-4-pyridinyl)propionamide;

N-[{3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-N-methyl-3-(3-pyrrolidinyl)propionamide;

N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-3-(3-fluoro-3-piperidinyl)-*N*-methylpropionamide;

N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-*N*-methyl-3-(2-morpholinyl)propionamide;

5 *N*-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-(3-piperidinyl)propionamide;
10 *N*-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-pyridinyl)propionamide;
and enantiomers, diastereoisomers, pharmaceutically acceptable salts(e.g hydrochloride) and solvates thereof.

7 A compound selected from

N-(*1R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide(diastereoisomer 1);

15 *N*-(*1S*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-*N*-methyl-3-(4-piperidinyl)propionamide (diastereoisomer 2);

***N*-(*1R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-methylpropionamide (diastereoisomer 1;**


N-(3,5-dibromophenyl)methyl]-3-(4-fluorophenyl)-3-(4-fluoro-4-piperidinyl)-*N*-

20 methylpropionamide (enantiomer 2);

N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-3-(4-fluorophenyl)-3-(3-fluoro-3-piperidinyl)-*N*-methylpropionamide (diastereoisomer A);

and pharmaceutically acceptable salts (e.g. hydrochloride) and solvates thereof.

25 8. A process for the preparation of a compound as claimed in claim 1 which comprises reacting an activated derivative of the carboxylic acid of formula (II) wherein R_1 has the meaning previously defined or is a protected group thereof, with amine (III)



30 wherein R_2 is C₁₋₄ alkyl or a nitrogen protecting group, followed where necessary by removal of any protecting group.

9. A compound as claimed in any claims 1 to 7 for use in therapy.

35 10. The use of a compound as claimed in any claims 1 to 7 in the preparation of a medicament for use in the treatment of conditions mediated by tachykinins (including

substance P and other neurokinins) and/or by selective inhibition of the serotonin reuptake transporter protein.

11. The use of a compound as claimed in any claims 1 to 7 in the treatment of

5 conditions mediated by tachykinins (including substance P and other neurokinins) and/or by selective inhibition of the serotonin reuptake transporter protein.

12. A pharmaceutical composition comprising a compound as claimed in any claims 1 to 7 in admixture with one or more pharmaceutically acceptable carriers or excipients.

10

13. A method for the treatment of a mammal, including man, in particular in the treatment of conditions mediated by tachykinins, including substance P and other neurokinins and/or by selective inhibition of the serotonin reuptake transporter protein comprising administration of an effective amount of a compound of formula (I) as claimed

15 in any claims 1 to 7.